Last week, we celebrated National Employee Appreciation Day, but at Alterome our gratitude extends far beyond just one day.? ? To our incredible team, your dedication, innovation, and passion are what make Alterome thrive. Your commitment to our mission of transforming the lives of cancer patients is our greatest strength. We truly appreciate each and every one of you.? ? Thank you for all that you do!? ? #EmployeeAppreciationDay #TeamAlterome #AlteromeTx?
关于我们
Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. We are a team with expertise in multiple areas of science and operations, dedicated to co-elevating toward our vision to bring life-changing and life-saving therapies to cancer patients. We believe in our journey, in each other, and in our ability to collaboratively develop therapies that will help end cancers. Thus, we seek the best people for our company and provide the resources they need to grow, develop, and accomplish our collective goals. We are moving forward with humility & empathy, fearlessness & resilience, with a sense of inclusion & belonging, open communication and a deep trust. And…we manage to have a lot of fun along the way!
- 网站
-
https://www.alterome.com
Alterome Therapeutics, Inc的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2021
地点
-
主要
获取路线
13480 Evening Creek Dr N
450
US，California，San Diego，92128
Alterome Therapeutics, Inc员工
动态
-
Today, we announce that the first patient?has been dosed in our Phase 1/1b trial of ALTA3263, a KRAS selective (ON/OFF) inhibitor, in adults with solid tumors with a KRAS mutation. Designed to address KRAS mutations in >20% of all patients with cancer, ALTA3263 represents a key step toward our mission to transform the lives of cancer patients, one alteration at a time. Read the full press release here: https://bwnews.pr/4ixQBve
-
-
Today, on International Women’s Day, we celebrate the remarkable achievements of women worldwide and recognize the incredible women who drive progress every day.? ? This year’s theme, Accelerate Action, is a call for urgency in breaking down systemic barriers and biases that persist in workplaces and beyond.? ? At Alterome, we are committed to fostering an environment where women innovate and shape the future.?? ? #IWD2025 #AccelerateAction #AlteromeTx??
-
-
Alterome’s management team will be participating in one-on-one investor meetings at two upcoming investor conferences: TD Cowen 45th Annual Health Care Conference and Leerink Partners Global Healthcare Conference.?Full press release: https://lnkd.in/dQf8e6jU
-
-
Today, we reflect on the #WorldCancerDay theme “United by Unique,” which places people at the center of their care and their stories at the heart of the conversation. At Alterome, we know that cancer is much more than a medical diagnosis, it is a unique human story. Our experience in oncology drives our commitment to precision medicine and targeting specific genetic alterations to transform the lives of patients one alteration at a time.? ? As we honor the stories at the heart of the cancer journey, we remain united in our mission to bring innovative therapies to those who need them most.? ? #UnitedByUnique #AlteromeTx #biotechnology?
-
-
We are grateful for the opportunity for Tim Sen Wang, Ph.D. to share the ALTA3263 story on behalf of?Alterome Therapeutics, Inc at the Champions Oncology, Inc. Translational Oncology Symposium. Please register below to attend the event.
?? We’re delighted to welcome Dr. Tim Sen Wang, as the next esteemed speaker for the Translational Oncology Symposium, happening on February 20, 2025, in La Jolla, CA! Dr. Wang, Associate Director of Discovery Biology at Alterome Therapeutics, Inc, leads innovative efforts to advance oncology programs from discovery to clinical stages. He’ll be presenting on: “ALTA3263: An oral, KRAS isoform-selective, dual ON/OFF state, non-covalent inhibitor induces regressions across KRAS mutant cancer models.” His talk promises to explore groundbreaking strategies to tackle RAS-driven cancers—a must-attend for oncology professionals and researchers. ?? Seats are complimentary but limited—register now to secure your spot : https://hubs.li/Q033835W0 #OncologyInnovation #CancerResearch#TranslationalOncology2025 #CancerTherapies #ImmunoOncology #PreclinicalResearch #OncologySymposium #RAS #KRAS #ProteinKinases #LipidKinases
-
-
Exciting company news: We announced today that the first patient has been dosed in our AKTive-001 trial of ALTA2618 evaluating patients with AKT1 E17K-mutant advanced solid tumors. Full press release to learn more: https://bwnews.pr/3A8O1eR
-
-
Alterome is presenting new preclinical data supporting the development of our KRAS-selective inhibitor, ALTA3263, at the EORTC-NCI-AACR symposium in Barcelona. #ENA2024 #KRAS Full press release: https://bwnews.pr/3Ah2xB5
-
We are thrilled to announce that Eric Murphy, CEO and co-founder of Alterome, has been recognized as one of the Most Exceptional Entrepreneurs of 2024 at Goldman Sachs Builders and Innovators Summit.?We are honored that Eric is included in this cohort of innovators!?#GSInnovators More details: https://bwnews.pr/4h5AdlN
-
-
We’re honored to be chosen as one of San Diego Business Journal’s Best Places to Work in 2024! At Alterome, we know the key to achieving our mission is through the collective success and respect of each team member as we commit to transform the lives of cancer patients, one alteration at a time.??
-